{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.9","upperLimit":"88.6","value":"83.8"}]}],"title":"Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"76.4","upperLimit":"86.4","value":"81.4"}]}],"title":"Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.2","upperLimit":"88.1","value":"83.2"}]}],"title":"Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"}],"units":"Participants"}],"description":"Negative Predictive Value (NPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The NPV is determined from the number of true negatives (negative 18F-DCFPyL image and a negative histopathology result for prostate cancer) divided by the number of participants with a negative 18F-DCFPyL image.","dispersionType":"95% Confidence Interval","groups":[{"description":"High risk prostate cancer participants planned for radical prostatectomy with pelvic lymph node dissection were enrolled to receive a single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL, followed by PET/CT imaging acquired 1-2 hours post-PyL injection.","id":"OG000","title":"High Risk Prostate Cancer (Cohort A)"}],"paramType":"NUMBER","populationDescription":"The Evaluable Set of high risk prostate cancer participants (Cohort A) includes those who received 18F-DCFPyL, had a prostatectomy or lymphadenectomy, and provided a 18F-DCFPyL PET/CT image result and a corresponding histopathology result.","reportingStatus":"POSTED","timeFrame":"Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.","title":"Negative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}